Revolutionizing Health: Cambridge Firm Innovates COVID Cure with Cutting-Edge AI Technology
Cambridge-based AI VIVO, a pioneering company at the intersection of artificial intelligence and systems pharmacology, is actively seeking partnerships with biotech and pharmaceutical firms to advance the promising candidate drugs it has identified as potential treatments for Covid-19. The company employs an innovative phenotypic drug discovery approach that operates independently of pre-existing knowledge about the disease.
AI VIVO has crafted a model utilizing Covid-19 infected cells, leading to the evaluation of 90,000 compounds based on their efficacy in combating viral infections, reducing inflammation, and mitigating cytokine storms—an excessive immune response by the body. From this extensive analysis, AI VIVO has meticulously narrowed down the candidates to a distinguished shortlist of 41 compounds, representing a mere 0.3 percent of the total assessed drugs. Notably, many of these candidates are already undergoing clinical trials worldwide.
Dr. Peyman Gifani, founder and CEO of AI VIVO, emphasizes that the company is intensifying its outreach to government agencies and pharmaceutical companies. The goal is to commence trials on combinations of other high-ranking compounds that have yet to be explored. “Our team of experts believes that certain combinations of these top-ranked drugs could prove more effective than any individual drug alone. We are eager to collaborate with pharmaceutical companies and clinical trial investigators to bolster the collective effort against Covid-19,” he stated.
Among AI VIVO’s elite selection of candidate drugs are several proprietary compounds currently in phase II or III clinical trials. The company is proactively engaging with pharmaceutical companies that have developed these compounds to discuss their relevance and potential applications as standalone therapies or in combination treatments.
